Effect of indomethacin plus ranitidine in advanced melanoma patients on high-dose interleukin-2

Lancet. 1992 Aug 15;340(8816):397-8. doi: 10.1016/0140-6736(92)91474-m.


Preclinical models of advanced melanoma have shown that chronic indomethacin therapy combined with interleukin 2 (IL-2) can eradicate experimental metastases. A phase II trial was done in patients with advanced melanoma. Indomethacin and ranitidine were begun at least one week before IL-2. Of the objective responses in 3 patients, 2 were achieved on ranitidine and indomethacin alone, before start of IL-2. Indomethacin and ranitidine may be responsible for some responses in melanoma patients previously attributed to IL-2.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Drug Evaluation
  • Female
  • Humans
  • Indomethacin / administration & dosage*
  • Interleukin-2 / administration & dosage
  • Male
  • Melanoma / drug therapy*
  • Middle Aged
  • Ranitidine / administration & dosage*


  • Interleukin-2
  • Ranitidine
  • Indomethacin